A Nuanced Approach:
Updates on GnRH Agonists for Ovarian Function Suppression
in the Management of Early-Stage Breast Cancer
Pre-test

Questions marked with a * are required

100%

Contact Information

First Name

Last Name

Email Address

AC is a 31-year-old woman presenting with a palpable right breast mass (6 cm, ER-positive, HER2-positive, node-positive), with a Recurrent Score (RS) of 9. Which of the following adjuvant treatment options would you most likely recommend for this patient?

Tamoxifen

Tamoxifen and oral function suppression (OFS)

Tamoxifen and aromatase inhibitor

OFS and aromatase inhibitor

Which of the following is TRUE about monthly vs. quarterly administration of GnRH agonists for the treatment of early-stage breast cancer?

Only monthly administration is recommended in the guidelines

Monthly administration is favored over quarterly administration

Trials have shown equivalent physiological and clinical outcomes between these two approaches

Trials have shown reduced physiological and clinical outcomes with quarterly administration

Based on current guidelines and data, what is the optimal duration of OFS for the treatment of premenopausal women with early-stage breast cancer?

6 months

1 year

2 years

3 years

4 years

5 years

CK is a 36-year-old premenopausal patient with node-negative localized breast cancer who is receiving OFS with a GnRH agonist in combination with tamoxifen and wishes to become pregnant. Based on current data, at minimum, how long should the duration of OFS be extended in this patient?

6 months

1 year

2 years

3 years

4 years

5 years

When considering GnRH agonists in addition to adjuvant chemotherapy for premenopausal patients with breast cancer for the purpose of fertility preservation, which of the following is TRUE compared to patients that received chemotherapy alone? Select all that apply

Reduction of risk of premature ovarian insufficiency with GnRH agonists

Increased incidence of amenorrhea with GnRH agonists

No improvement in pregnancy rates with GnRH agonists

Significant improvement in pregnancy rates with GnRH agonists

Lower rates of disease-free survival and overall survival with GnRH agonists